New shot aims to slash hidden heart risk in 203 patients
NCT ID NCT07185776
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called HRS-5632 in 203 adults with high levels of lipoprotein(a), a fatty substance that raises the risk of heart attacks and strokes. Participants receive either the drug or a placebo to see if the drug safely lowers this substance. The goal is to find a new way to control heart disease risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIPOPROTEIN DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Xi'an Jiaotong University
Xi’an, Shanxi, 710061, China
-
The Second Affiliated Hospital of AFMU
Xi’an, Shanxi, 710038, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Will a new drug formula absorb better? a trial in healthy adults aims to find out
- Scientists create a 'Lipid Library' to unlock secrets of rare cholesterol conditions
- New drug Kylo-11 aims to tackle stubborn heart disease risk factor
- New study probes hidden heart risk from common blood fat
- New shot aims to tackle hidden heart risk: high lp(a)